CSL Limited (CSLLY)
OTHER OTC:CSLLY
Want to see CSLLY full AI Analyst Report?
CSLLY Stock Chart & Stats
$58.43
$0.39(0.44%)
At close: 4:00 PM EST
$58.43
$0.39(0.44%)
Day’s Range― - ―
52-Week Range$22.35 - $44.53
Previous CloseN/A
Volume10.38K
Average Volume (3M)1.91K
Market Cap
$43.23B
Enterprise Value$54.49B
Total Cash (Recent Filing)$1.15B
Total Debt (Recent Filing)$12.57B
Price to Earnings (P/E)69.3
Beta0.37
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.33%
Share Statistics
EPS (TTM)0.06
Shares Outstanding1,941,275,900
10 Day Avg. Volume0
30 Day Avg. Volume1,912
Financial Highlights & Ratios
PEG Ratio3.83
Price to Book (P/B)7.93
Price to Sales (P/S)9.94
P/FCF Ratio60.28
Enterprise Value/Market Cap1.26
Enterprise Value/Revenue3.50
Enterprise Value/Gross Profit7.20
Enterprise Value/Ebitda10.70
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Free Cash FlowSustained FCF growth and efficient cash conversion provide durable funding for R&D, capex, dividends and buybacks. High conversion ratios reduce reliance on external financing and give flexibility to execute transformation plans and absorb near-term earnings volatility over coming quarters.
Vertically Integrated Plasma ModelOwning plasma collection through to manufacturing creates a structural supply advantage and cost control that supports margins and product security. This vertical moat underpins recurring revenue from chronic therapies and reduces exposure to third-party supply shocks over the medium term.
Successful Specialty Launches & PipelineRapid adoption of high-value specialty therapies and an advancing pipeline broaden future revenue streams and bolster margin profile. Durable uptake of launched products plus progressing candidates (Phase III outlook) support medium-term growth and reduce reliance on legacy portfolios.
Bears Say
Large Noncash ImpairmentsMaterial impairments signal overhang from assets not meeting prior expectations, reducing reported earnings and tangible equity. These write-downs produce lasting volatility in reported metrics, constrain headline profitability and may limit near-term capital allocation flexibility.
Ig Franchise Reimbursement HeadwindsReimbursement and contract losses on core immunoglobulin products weaken predictability of a primary revenue engine. Given Ig's centrality, sustained payer policy shifts and contract dynamics can depress volumes and pricing power for multiple quarters, pressuring margins and cash flow.
Generics And LOE In Iron FranchiseEstablished product sales face structural decline from generics and impending loss of exclusivity, eroding revenues and margin contribution. These secular competitive pressures can reduce segment cash flow and require redeployment of salesforce and R&D resources to offset declines over the next 2–6 months.
CSL News
CSLLY FAQ
What was CSL Limited’s price range in the past 12 months?
CSL Limited lowest stock price was $22.35 and its highest was $44.53 in the past 12 months.
What is CSL Limited’s market cap?
CSL Limited’s market cap is $43.23B.
When is CSL Limited’s upcoming earnings report date?
CSL Limited’s upcoming earnings report date is Aug 18, 2026 which is in 104 days.
How were CSL Limited’s earnings last quarter?
CSL Limited released its earnings results on Feb 10, 2026. The company reported $0.208 earnings per share for the quarter, beating the consensus estimate of N/A by $0.208.
Is CSL Limited overvalued?
According to Wall Street analysts CSL Limited’s price is currently Overvalued.
Does CSL Limited pay dividends?
CSL Limited pays a Semiannually dividend of $0.76 which represents an annual dividend yield of 2.33%. See more information on CSL Limited dividends here
What is CSL Limited’s EPS estimate?
CSL Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CSL Limited have?
CSL Limited has 1,941,275,900 shares outstanding.
What happened to CSL Limited’s price movement after its last earnings report?
CSL Limited reported an EPS of $0.208 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -4.342%.
Which hedge fund is a major shareholder of CSL Limited?
Currently, no hedge funds are holding shares in CSLLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSL Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
CSLLY Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 66.1K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.06%
12-Months-Change
Fundamentals
Return on Equity
7.56%
Trailing 12-Months
Asset Growth
-1.42%
Trailing 12-Months
Company Description
CSL Limited
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
CSLLY Company Deck
CSLLY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: solid cash generation, strong specialty product launches (HEMGENIX, ANDEMBRY), Seqirus market-share gains and meaningful progress on a large transformation program were balanced against meaningful near-term headwinds — including revenue declines, large noncash impairments (~$1.1bn), product and market-specific pressures (Ig Medicare Part D impact, albumin policy impact in China, iron generics, and impending reimbursement changes for Velphoro). Management maintained guidance, expanded capital returns, and outlined concrete remediation actions, but several challenges will weigh on reported earnings in the near term.View all CSLLY earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---